bosentan anhydrous has been researched along with transforming growth factor beta in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hannan, RD; Krum, H; Lim, S; See, F; Tzanidis, A; Ugoni, AM | 1 |
| Bernal, R; Blanco, J; Egido, J; Gomez-Garre, D; Gomez-Guerrero, C; Lopez-Franco, O; Ortega, L; Sugaya, T; Suzuki, Y; Tejera, N | 1 |
| Chen, J; Gu, Y; Lin, F; Lin, S; Ma, J; Yang, H; Zhu, W | 1 |
| Bellini, G; Bernobich, E; Borri, A; Cosenzi, A; Milutinovic, N; Trevisan, R | 1 |
| Chakrabarti, S; Cukiernik, M; Gonder, JR; Khan, ZA | 1 |
| Abraham, DJ; Black, CM; Bou-Gharios, G; Denton, CP; du Bois, RM; Kennedy, L; Leask, A; Renzoni, EA; Shi-wen, X | 1 |
| Silver, RM | 1 |
| Sirmagul, B; Yigitaslan, S | 1 |
| Ayaz, G; Baygutalp, NK; Bayir, Y; Calik, M; Demirci, E; Ferah, I; Gundogdu, C; Ozkanlar, S | 1 |
| Akpinar, E; Albayrak, A; Atmaca, HT; Bayraktutan, Z; Cayir, A; Cayir, Y; Kara, M; Kose, D; Ugan, RA | 1 |
| Babaahmadi-Rezaei, H; Dayati, P; Ghaffari, MA; Kamato, D; Little, PJ; Mohammad Zadeh, G; Sharifat, N | 1 |
1 review(s) available for bosentan anhydrous and transforming growth factor beta
| Article | Year |
|---|---|
Endothelin and scleroderma lung disease.
Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Humans; Lung Diseases, Interstitial; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Sulfonamides; Transforming Growth Factor beta; Treatment Failure | 2008 |
10 other study(ies) available for bosentan anhydrous and transforming growth factor beta
| Article | Year |
|---|---|
Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1).
Topics: Angiotensin Receptor Antagonists; Animals; Blotting, Northern; Bosentan; Collagen; Endothelin Receptor Antagonists; Female; Fibroblasts; Hemodynamics; Hypertrophy, Left Ventricular; Immunohistochemistry; Macrophages; Monocytes; Myocardial Infarction; Myocardium; Procollagen; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides; Tetrazoles; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan; Ventricular Dysfunction, Left | 2001 |
Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice: role of endothelin-1.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Bosentan; Endothelins; Extracellular Matrix; Isoquinolines; Kidney; Kidney Diseases; Kidney Tubules; Kinetics; Mice; Mice, Inbred C57BL; Mice, Knockout; NF-kappa B; Proteinuria; Quinapril; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Reference Values; RNA, Messenger; Serum Albumin, Bovine; Sulfonamides; Tetrahydroisoquinolines; Transcription Factor AP-1; Transforming Growth Factor beta | 2001 |
Endothelin receptor antagonist combined with a calcium channel blocker attenuates renal injury in spontaneous hypertensive rats with diabetes.
Topics: Amlodipine; Angiotensin II; Animals; Bosentan; Calcium Channel Blockers; Collagen Type IV; Diabetic Nephropathies; Drug Therapy, Combination; Endothelin Receptor Antagonists; Hypertension; Kidney; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Sulfonamides; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2002 |
Nephroprotective effect of bosentan in diabetic rats.
Topics: Animals; Blood Glucose; Bosentan; Collagen; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelin Receptor Antagonists; Fibronectins; Kidney; Rats; Rats, Inbred WKY; Sulfonamides; Transforming Growth Factor beta | 2003 |
Oncofetal fibronectin in diabetic retinopathy.
Topics: Aged; Animals; Blotting, Western; Bosentan; Cell Division; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelin-1; Endothelium, Vascular; Female; Fibronectins; Gene Silencing; Humans; Male; Middle Aged; Rats; Rats, Sprague-Dawley; Retinal Perforations; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Transforming Growth Factor beta; Transforming Growth Factor beta1; Up-Regulation; Vitrectomy; Vitreous Body | 2004 |
Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts.
Topics: Bosentan; Cells, Cultured; Collagen Type I; Connective Tissue Growth Factor; Endothelin Receptor Antagonists; Endothelin-1; Extracellular Matrix; Fibroblasts; Fibronectins; Gene Expression Profiling; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Lung; Phenotype; Pulmonary Fibrosis; Sulfonamides; Transforming Growth Factor beta | 2007 |
Relation of bosentan, iloprost, and sildenafil with growth factor levels in monocrotaline-induced pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Female; Hypertension, Pulmonary; Iloprost; Monocrotaline; Piperazines; Pulmonary Artery; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfonamides; Sulfones; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A; Vasodilator Agents | 2012 |
Endothelin receptor inhibition with bosentan delays onset of liver injury in streptozotocin-induced diabetic condition.
Topics: Animals; Bosentan; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Experimental; Endothelin Receptor Antagonists; Endothelin-1; Gene Expression Regulation; Glutathione; Liver; Male; Malondialdehyde; Rats; Streptozocin; Sulfonamides; Superoxide Dismutase; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2015 |
The lung endothelin system: a potent therapeutic target with bosentan for the amelioration of lung alterations in a rat model of diabetes mellitus.
Topics: Acute Lung Injury; Animals; Bosentan; Diabetes Mellitus, Experimental; Endothelin Receptor Antagonists; Glutathione; Lung; Male; Malondialdehyde; Oxidative Stress; Rats; Rats, Wistar; Sulfonamides; Superoxide Dismutase; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2015 |
Endothelin-1 (ET-1) stimulates carboxy terminal Smad2 phosphorylation in vascular endothelial cells by a mechanism dependent on ET receptors and de novo protein synthesis.
Topics: Animals; Benzamides; Bosentan; Cattle; Cycloheximide; Dioxoles; Endothelial Cells; Endothelin Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Enzyme Inhibitors; Phosphorylation; Protein Biosynthesis; Protein Synthesis Inhibitors; Receptor, Endothelin B; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad2 Protein; Sulfonamides; Transforming Growth Factor beta | 2017 |